Symbols

BCYC

Bicycle Therapeutics·NASDAQ

--(--)

Signals Analysis

Bullish signal 4

Bearish signal 1

Consensus Rating "Buy"

Ample Liquidity

High Gross Profit Margin

Revenue Beats Expectation

EPS Below Expectations

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About BCYC

Bicycle Therapeutics Plc

A clinical-stage biopharmaceutical company developing a novel class of medicines, referred to as Bicycles, for diseases that are underserved by existing therapeutics

Industry

Pharmaceutical

Established Date

10/27/2017

Listing Date

05/23/2019

Exchange

NASDAQ Stock Exchange

Full-time Employees

288

Fiscal Year Ends

12-31

Website

www.bicycletherapeutics.com

Security Type

Depository Receipts (Ordinary Shares)

Office address

Blocks A & B, Portway Building, Granta Park, Great Abington, Cambridge, United Kingdom, CB21 6GS

Business

Introduction

Bicycle Therapeutics plc was incorporated under the laws of England and Wales on 27 October 2017. The company is a clinical-stage biopharmaceutical company developing a new class of drugs, which they call bicycle molecules, for diseases for which existing treatments are insufficient. Bicycle molecules are fully synthesized short peptides that limit the formation of two rings, stabilizing their structural geometry. This constraint is designed to confer high affinity and selectivity, and the relatively large surface area presented by the molecule allows targeting of drugs, which has historically been difficult to handle with non-biological methods. Bicycle molecules are a unique therapeutic modality that combines pharmacology, usually associated with biological agents, with the manufacture and pharmacokinetic or PK properties of small molecules.

Company Financials

EPS

BCYC has released its 2025 Q4 earnings. EPS was reported at -0.29, versus the expected -0.97, beating expectations. The chart below visualizes how BCYC has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

BCYC has released its 2025 Q4 earnings report, with revenue of 47.95M, reflecting a YoY change of 1193.28%, and net profit of -20.15M, showing a YoY change of 61.13%. The Sankey diagram below clearly presents BCYC's revenue sources and cost distribution.